Global Opioid Tolerance Treatment Market: Industry Analysis and forecast (2019 to 2026): By Drug Type, Administration route, Type, End Users, and Region

Global Opioid Tolerance Treatment Market: Industry Analysis and forecast (2019 to 2026): By Drug Type, Administration route, Type, End Users, and Region

Market Scenario

Global Opioid Tolerance Treatment Market was valued US$ XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of XX% during forecast period of 2019 to 2026 Global Opioid Tolerance Treatment Market Global Opioid Tolerance Treatment Market Drivers and Restrains Opioid tolerance can be defined as a decrease in analgesic response with increasing dose or frequency of administration. Tolerance is the greatest obstacle to the development of effective opioid treatment for intractable pain. Tolerance to endogenous opioids is often rapid, whereas tolerance to exogenous opioids is often delayed. Rise in opioid consumption worldwide for medical and non-medical purpose and large number of opioid prescription dispensed for therapeutic purposes are expected to propel the global opioid tolerance market. Increasing prevalence of diseases that cause chronic pain, such as cancer, postsurgical pain, lower back pain, fibromyalgia, and arthritis will fuel the global market in forecast period. Opioid Tolerance phenomenon in which repeated exposure to opioid results in decreased therapeutic effect of drug or need of higher dose to maintain opioid effect is considered to be the major restraint to the global market.The report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis. Global Opioid Tolerance Treatment Market By key segmentation Global Opioid Tolerance Treatment Market is segmented in to drug Type, administration route, Tolerance type and End Users. Based on by Drug type market is divided into NMDA Antagonists, Alpha2-Adrenoceptor Agonists and Others.Alpha2-adrenoceptor agonists is sub-divided into Clonidine, Tizanidine, and others. And The NMDA antagonists segment is sub-divided into Dextromethorphan, Ketamine, and others. Alpha2-adrenoceptor agonists accounted for the largest market share of around XX% and are expected to remain dominant over the forecast time period. Because of improved efficacy for opioids tolerance and reduced side-effects. By End-User market is segmented into Hospitals and ASCs, Rehabilitation Centers and Others (Homecare Settings and Research Institutes).Hospitals dominated the opioid tolerance treatment market in 2018 globally, due to growing patient admissions for treating cancer and chronic pain along with these setting being equipped with better facilities. Global Opioid Tolerance Treatment Market Regional Analysis Global Opioid Tolerance Treatment Market by region is segmented into Asia Pacific, North America, Europe, Latin America and Middle East Africa. The North America dominated the Global Market in 2018, because of Growth in the Incidence of Orthopedic Diseases & Chronic Pain and rise in knowledge about among healthcare professionals. The Asia Pacific region is expected to register a high growth rate in the global opioid tolerance treatment market because mounting Demand from Emerging Economic such as China, India, and Cambodia. High prevalence of chronic diseases and pain associated with such diseases along with the increasing aging regional population, as geriatric people in European countries will propel global market in this region .Latin America and Middle East and Africa regions accounted for the minimum shares of the global opioid tolerance treatment market, owing to the low awareness among the people about these treatments and low affordability rate for such treatment options. The objective of the report is to present comprehensive analysis of Global Opioid Tolerance Treatment Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Opioid Tolerance Treatment Market dynamics, structure by analyzing the market segments, and project the Global Opioid Tolerance Treatment Market size. Clear representation of competitive analysis of key players by Opioid Tolerance Treatment Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Opioid Tolerance Treatment Market make the report investor’s guide.

Scope of Global Opioid Tolerance Treatment Market

Global Opioid Tolerance Treatment Market by Drug type

• NMDA Antagonists • Alpha2-Adrenoceptor Agonists • Others

Global Opioid Tolerance Treatment Market by Administration Route

• Enteral • Parenteral • Others (including Transdermal Route, Patches, and Cartons of Patches)

Global Opioid Tolerance Treatment Market by End-User

• Hospitals and ASCs • Rehabilitation Centers • Others (Homecare Settings and Research Institutes)

Global Opioid Tolerance Treatment Market by region

• Asia Pacific • North America • Europe • Latin America • Middle East Africa

Key players operating on Global Opioid Tolerance Treatment Market

• Pfizer, • GlaxoSmithKline, • Boehringer Ingelheim, • Teva Pharmaceutical, • Mylan, • Otsuka Pharmaceutical, • Johnson & Johnson, • Aurobindo Pharma, • Acorda Therapeutics, • Zydus Cadila • Purdue Pharma, • Boehringer Ingelheim, • Janssen Pharmaceuticals, Inc., • Actavis Plc., • Sanofi, • Sun Pharmaceutical Industries Ltd., • Mallinckrodt Pharmaceuticals,

Table of Contents

Global Opioid Tolerance Treatment Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Opioid Tolerance Treatment Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Opioid Tolerance Treatment Market Analysis and Forecast 6.1. Global Opioid Tolerance Treatment Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Opioid Tolerance Treatment Market Analysis and Forecast, by Drug type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Opioid Tolerance Treatment Market Value Share Analysis, by Drug type 7.4. Global Opioid Tolerance Treatment Market Size (US$ Bn) Forecast, by Drug type 7.5. Global Opioid Tolerance Treatment Market Analysis, by Drug type 7.6. Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Drug type 8. Global Opioid Tolerance Treatment Market Analysis and Forecast, by Administration route 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Opioid Tolerance Treatment Market Value Share Analysis, by Administration route 8.4. Global Opioid Tolerance Treatment Market Size (US$ Bn) Forecast, by Administration route 8.5. Global Opioid Tolerance Treatment Market Analysis, by Administration route 8.6. Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Administration route 9. Global Opioid Tolerance Treatment Market Analysis and Forecast, by End-use 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Opioid Tolerance Treatment Market Value Share Analysis, by End-use 9.4. Global Opioid Tolerance Treatment Market Size (US$ Bn) Forecast, by End-use 9.5. Global Opioid Tolerance Treatment Market Analysis, by End-use 9.6. Global Opioid Tolerance Treatment Market Attractiveness Analysis, by End-use 10. Global Opioid Tolerance Treatment Market Analysis, by Region 10.1. Global Opioid Tolerance Treatment Market Value Share Analysis, by Region 10.2. Global Opioid Tolerance Treatment Market Size (US$ Bn) Forecast, by Region 10.3. Global Opioid Tolerance Treatment Market Attractiveness Analysis, by Region 11. North America Opioid Tolerance Treatment Market Analysis 11.1. Key Findings 11.2. North America Opioid Tolerance Treatment Market Overview 11.3. North America Opioid Tolerance Treatment Market Value Share Analysis, by Drug type 11.4. North America Opioid Tolerance Treatment Market Forecast, by Drug type 11.4.1. NMDA Antagonists 11.4.2. Alpha2-Adrenoceptor Agonists 11.4.3. Others 11.5. North America Opioid Tolerance Treatment Market Value Share Analysis, by Administration route 11.6. North America Opioid Tolerance Treatment Market Forecast, by Administration route 11.6.1. Enteral 11.6.2. Parenteral 11.6.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 11.7. North America Opioid Tolerance Treatment Market Value Share Analysis, by End-use 11.8. North America Opioid Tolerance Treatment Market Forecast, by End-use 11.8.1. Hospitals and ASCs 11.8.2. Rehabilitation Centers 11.8.3. Others (Homecare Settings and Research Institutes) 11.9. North America Opioid Tolerance Treatment Market Value Share Analysis, by Country 11.10. North America Opioid Tolerance Treatment Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Opioid Tolerance Treatment Market Analysis, by Country 11.12. U.S. Opioid Tolerance Treatment Market Forecast, by Drug type 11.12.1. NMDA Antagonists 11.12.2. Alpha2-Adrenoceptor Agonists 11.12.3. Others 11.13. U.S. Opioid Tolerance Treatment Market Forecast, by Administration route 11.13.1. Enteral 11.13.2. Parenteral 11.13.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 11.14. U.S. Opioid Tolerance Treatment Market Forecast, by End-use 11.14.1. Hospitals and ASCs 11.14.2. Rehabilitation Centers 11.14.3. Others (Homecare Settings and Research Institutes) 11.15. Canada Opioid Tolerance Treatment Market Forecast, by Drug type 11.15.1. NMDA Antagonists 11.15.2. Alpha2-Adrenoceptor Agonists 11.15.3. Others 11.16. Steel Canada Opioid Tolerance Treatment Market Forecast, by Administration route 11.16.1. Enteral 11.16.2. Parenteral 11.16.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 11.17. Canada Opioid Tolerance Treatment Market Forecast, by End-use 11.17.1. Hospitals and ASCs 11.17.2. Rehabilitation Centers 11.17.3. Others (Homecare Settings and Research Institutes) 11.18. North America Opioid Tolerance Treatment Market Attractiveness Analysis 11.18.1. By Drug type 11.18.2. By Administration route 11.18.3. By End-use 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Opioid Tolerance Treatment Market Analysis 12.1. Key Findings 12.2. Europe Opioid Tolerance Treatment Market Overview 12.3. Europe Opioid Tolerance Treatment Market Value Share Analysis, by Drug type 12.4. Europe Opioid Tolerance Treatment Market Forecast, by Drug type 12.4.1. NMDA Antagonists 12.4.2. Alpha2-Adrenoceptor Agonists 12.4.3. Others 12.5. Europe Opioid Tolerance Treatment Market Value Share Analysis, by Administration route 12.6. Europe Opioid Tolerance Treatment Market Forecast, by Administration route 12.6.1. Enteral 12.6.2. Parenteral 12.6.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.7. Europe Opioid Tolerance Treatment Market Value Share Analysis, by End-use 12.8. Europe Opioid Tolerance Treatment Market Forecast, by End-use 12.8.1. Hospitals and ASCs 12.8.2. Rehabilitation Centers 12.8.3. Others (Homecare Settings and Research Institutes) 12.9. Europe Opioid Tolerance Treatment Market Value Share Analysis, by Country 12.10. Europe Opioid Tolerance Treatment Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Opioid Tolerance Treatment Market Analysis, by Country 12.12. Germany Opioid Tolerance Treatment Market Forecast, by Drug type 12.12.1. NMDA Antagonists 12.12.2. Alpha2-Adrenoceptor Agonists 12.12.3. Others 12.13. Germany Opioid Tolerance Treatment Market Forecast, by Administration route 12.13.1. Enteral 12.13.2. Parenteral 12.13.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.14. Germany Opioid Tolerance Treatment Market Forecast, by End-use 12.14.1. Hospitals and ASCs 12.14.2. Rehabilitation Centers 12.14.3. Others (Homecare Settings and Research Institutes) 12.15. U.K. Opioid Tolerance Treatment Market Forecast, by Drug type 12.15.1. NMDA Antagonists 12.15.2. Alpha2-Adrenoceptor Agonists 12.15.3. Others 12.16. U.K. Opioid Tolerance Treatment Market Forecast, by Administration route 12.16.1. Enteral 12.16.2. Parenteral 12.16.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.17. U.K. Opioid Tolerance Treatment Market Forecast, by End-use 12.17.1. Hospitals and ASCs 12.17.2. Rehabilitation Centers 12.17.3. Others (Homecare Settings and Research Institutes) 12.18. France Opioid Tolerance Treatment Market Forecast, by Drug type 12.18.1. NMDA Antagonists 12.18.2. Alpha2-Adrenoceptor Agonists 12.18.3. Others 12.19. France Opioid Tolerance Treatment Market Forecast, by Administration route 12.19.1. Enteral 12.19.2. Parenteral 12.19.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.20. France Opioid Tolerance Treatment Market Forecast, by End-use 12.20.1. Hospitals and ASCs 12.20.2. Rehabilitation Centers 12.20.3. Others (Homecare Settings and Research Institutes) 12.21. Italy Opioid Tolerance Treatment Market Forecast, by Drug type 12.21.1. NMDA Antagonists 12.21.2. Alpha2-Adrenoceptor Agonists 12.21.3. Others 12.22. Italy Opioid Tolerance Treatment Market Forecast, by Administration route 12.22.1. Enteral 12.22.2. Parenteral 12.22.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.23. Italy Opioid Tolerance Treatment Market Forecast, by End-use 12.23.1. Hospitals and ASCs 12.23.2. Rehabilitation Centers 12.23.3. Others (Homecare Settings and Research Institutes) 12.24. Spain Opioid Tolerance Treatment Market Forecast, by Drug type 12.24.1. NMDA Antagonists 12.24.2. Alpha2-Adrenoceptor Agonists 12.24.3. Others  12.25. Spain Opioid Tolerance Treatment Market Forecast, by Administration route 12.25.1. Enteral 12.25.2. Parenteral 12.25.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.26. Spain Opioid Tolerance Treatment Market Forecast, by End-use 12.26.1. Hospitals and ASCs 12.26.2. Rehabilitation Centers 12.26.3. Others (Homecare Settings and Research Institutes) 12.27. Rest of Europe Opioid Tolerance Treatment Market Forecast, by Drug type 12.27.1. NMDA Antagonists 12.27.2. Alpha2-Adrenoceptor Agonists 12.27.3. Others 12.28. Rest of Europe Opioid Tolerance Treatment Market Forecast, by Administration route 12.28.1. Enteral 12.28.2. Parenteral 12.28.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 12.29. Rest Of Europe Opioid Tolerance Treatment Market Forecast, by End-use 12.29.1. Hospitals and ASCs 12.29.2. Rehabilitation Centers 12.29.3. Others (Homecare Settings and Research Institutes) 12.30. Europe Opioid Tolerance Treatment Market Attractiveness Analysis 12.30.1. By Drug type 12.30.2. By Administration route 12.30.3. By End-use 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Opioid Tolerance Treatment Market Analysis 13.1. Key Findings 13.2. Asia Pacific Opioid Tolerance Treatment Market Overview 13.3. Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Drug type 13.4. Asia Pacific Opioid Tolerance Treatment Market Forecast, by Drug type 13.4.1. NMDA Antagonists 13.4.2. Alpha2-Adrenoceptor Agonists 13.4.3. Others 13.5. Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Administration route 13.6. Asia Pacific Opioid Tolerance Treatment Market Forecast, by Administration route 13.6.1. Enteral 13.6.2. Parenteral 13.6.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 13.7. Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by End-use 13.8. Asia Pacific Opioid Tolerance Treatment Market Forecast, by End-use 13.8.1. Hospitals and ASCs 13.8.2. Rehabilitation Centers 13.8.3. Others (Homecare Settings and Research Institutes) 13.9. Asia Pacific Opioid Tolerance Treatment Market Value Share Analysis, by Country 13.10. Asia Pacific Opioid Tolerance Treatment Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Opioid Tolerance Treatment Market Analysis, by Country 13.12. China Opioid Tolerance Treatment Market Forecast, by Drug type 13.12.1. NMDA Antagonists 13.12.2. Alpha2-Adrenoceptor Agonists 13.12.3. Others 13.13. China Opioid Tolerance Treatment Market Forecast, by Administration route 13.13.1. Enteral 13.13.2. Parenteral 13.13.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 13.14. China Opioid Tolerance Treatment Market Forecast, by End-use 13.14.1. Hospitals and ASCs 13.14.2. Rehabilitation Centers 13.14.3. Others (Homecare Settings and Research Institutes) 13.15. India Opioid Tolerance Treatment Market Forecast, by Drug type 13.15.1. NMDA Antagonists 13.15.2. Alpha2-Adrenoceptor Agonists 13.15.3. Others 13.16. India Opioid Tolerance Treatment Market Forecast, by Administration route 13.16.1. Enteral 13.16.2. Parenteral 13.16.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 13.17. India Opioid Tolerance Treatment Market Forecast, by End-use 13.17.1. Hospitals and ASCs 13.17.2. Rehabilitation Centers 13.17.3. Others (Homecare Settings and Research Institutes) 13.18. Japan Opioid Tolerance Treatment Market Forecast, by Drug type 13.18.1. NMDA Antagonists 13.18.2. Alpha2-Adrenoceptor Agonists 13.18.3. Others 13.19. Japan Opioid Tolerance Treatment Market Forecast, by Administration route 13.19.1. Enteral 13.19.2. Parenteral 13.19.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 13.20. Japan Opioid Tolerance Treatment Market Forecast, by End-use 13.20.1. Hospitals and ASCs 13.20.2. Rehabilitation Centers 13.20.3. Others (Homecare Settings and Research Institutes) 13.21. ASEAN Opioid Tolerance Treatment Market Forecast, by Drug type 13.21.1. NMDA Antagonists 13.21.2. Alpha2-Adrenoceptor Agonists 13.21.3. Others 13.22. ASEAN Opioid Tolerance Treatment Market Forecast, by Administration route 13.22.1. Enteral 13.22.2. Parenteral 13.22.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 13.23. ASEAN Opioid Tolerance Treatment Market Forecast, by End-use 13.23.1. Hospitals and ASCs 13.23.2. Rehabilitation Centers 13.23.3. Others (Homecare Settings and Research Institutes) 13.24. Rest of Asia Pacific Opioid Tolerance Treatment Market Forecast, by Drug type 13.24.1. NMDA Antagonists 13.24.2. Alpha2-Adrenoceptor Agonists 13.24.3. Others 13.25. Rest of Asia Pacific Opioid Tolerance Treatment Market Forecast, by Administration route 13.25.1. Enteral 13.25.2. Parenteral 13.25.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 13.26. Rest of Asia Pacific Opioid Tolerance Treatment Market Forecast, by End-use 13.26.1. Hospitals and ASCs 13.26.2. Rehabilitation Centers 13.26.3. Others (Homecare Settings and Research Institutes) 13.27. Asia Pacific Opioid Tolerance Treatment Market Attractiveness Analysis 13.27.1. By Drug type 13.27.2. By Administration route 13.27.3. By End-use 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Opioid Tolerance Treatment Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Opioid Tolerance Treatment Market Overview 14.3. Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Drug type 14.4. Middle East & Africa Opioid Tolerance Treatment Market Forecast, by Drug type 14.4.1. NMDA Antagonists 14.4.2. Alpha2-Adrenoceptor Agonists 14.4.3. Others 14.5. Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Administration route 14.6. Middle East & Africa Opioid Tolerance Treatment Market Forecast, by Administration route 14.6.1. Enteral 14.6.2. Parenteral 14.6.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 14.7. Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by End-use 14.8. Middle East & Africa Opioid Tolerance Treatment Market Forecast, by End-use 14.8.1. Hospitals and ASCs 14.8.2. Rehabilitation Centers 14.8.3. Others (Homecare Settings and Research Institutes) 14.9. Middle East & Africa Opioid Tolerance Treatment Market Value Share Analysis, by Country 14.10. Middle East & Africa Opioid Tolerance Treatment Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Opioid Tolerance Treatment Market Analysis, by Country 14.12. GCC Opioid Tolerance Treatment Market Forecast, by Drug type 14.12.1. NMDA Antagonists 14.12.2. Alpha2-Adrenoceptor Agonists 14.12.3. Others 14.13. GCC Opioid Tolerance Treatment Market Forecast, by Administration route 14.13.1. Enteral 14.13.2. Parenteral 14.13.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 14.14. GCC Opioid Tolerance Treatment Market Forecast, by End-use 14.14.1. Hospitals and ASCs 14.14.2. Rehabilitation Centers 14.14.3. Others (Homecare Settings and Research Institutes) 14.15. South Africa Opioid Tolerance Treatment Market Forecast, by Drug type 14.15.1. NMDA Antagonists 14.15.2. Alpha2-Adrenoceptor Agonists 14.15.3. Others 14.16. South Africa Opioid Tolerance Treatment Market Forecast, by Administration route 14.16.1. Enteral 14.16.2. Parenteral 14.16.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 14.17. South Africa Opioid Tolerance Treatment Market Forecast, by End-use 14.17.1. Hospitals and ASCs 14.17.2. Rehabilitation Centers 14.17.3. Others (Homecare Settings and Research Institutes) 14.18. Rest of Middle East & Africa Opioid Tolerance Treatment Market Forecast, by Drug type 14.18.1. NMDA Antagonists 14.18.2. Alpha2-Adrenoceptor Agonists 14.18.3. Others 14.19. Rest of Middle East & Africa Opioid Tolerance Treatment Market Forecast, by Administration route 14.19.1. Enteral 14.19.2. Parenteral 14.19.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 14.20. Rest of Middle East & Africa Opioid Tolerance Treatment Market Forecast, by End-use 14.20.1. Hospitals and ASCs 14.20.2. Rehabilitation Centers 14.20.3. Others (Homecare Settings and Research Institutes) 14.21. Middle East & Africa Opioid Tolerance Treatment Market Attractiveness Analysis 14.21.1. By Drug type 14.21.2. By Administration route 14.21.3. By End-use 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Opioid Tolerance Treatment Market Analysis 15.1. Key Findings 15.2. South America Opioid Tolerance Treatment Market Overview 15.3. South America Opioid Tolerance Treatment Market Value Share Analysis, by Drug type 15.4. South America Opioid Tolerance Treatment Market Forecast, by Drug type 15.4.1. NMDA Antagonists 15.4.2. Alpha2-Adrenoceptor Agonists 15.4.3. Others 15.5. South America Opioid Tolerance Treatment Market Value Share Analysis, by Administration route 15.6. South America Opioid Tolerance Treatment Market Forecast, by Administration route 15.6.1. Enteral 15.6.2. Parenteral 15.6.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 15.7. South America Opioid Tolerance Treatment Market Value Share Analysis, by End-use 15.8. South America Opioid Tolerance Treatment Market Forecast, by End-use 15.8.1. Hospitals and ASCs 15.8.2. Rehabilitation Centers 15.8.3. Others (Homecare Settings and Research Institutes) 15.9. South America Opioid Tolerance Treatment Market Value Share Analysis, by Country 15.10. South America Opioid Tolerance Treatment Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Opioid Tolerance Treatment Market Analysis, by Country 15.12. Brazil Opioid Tolerance Treatment Market Forecast, by Drug type 15.12.1. NMDA Antagonists 15.12.2. Alpha2-Adrenoceptor Agonists 15.12.3. Others 15.13. Brazil Opioid Tolerance Treatment Market Forecast, by Administration route 15.13.1. Enteral 15.13.2. Parenteral 15.13.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 15.14. Brazil Opioid Tolerance Treatment Market Forecast, by End-use 15.14.1. Hospitals and ASCs 15.14.2. Rehabilitation Centers 15.14.3. Others (Homecare Settings and Research Institutes) 15.15. Mexico Opioid Tolerance Treatment Market Forecast, by Drug type 15.15.1. NMDA Antagonists 15.15.2. Alpha2-Adrenoceptor Agonists 15.15.3. Others 15.16. Mexico Opioid Tolerance Treatment Market Forecast, by Administration route 15.16.1. Enteral 15.16.2. Parenteral 15.16.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 15.17. Mexico Opioid Tolerance Treatment Market Forecast, by End-use 15.17.1. Hospitals and ASCs 15.17.2. Rehabilitation Centers 15.17.3. Others (Homecare Settings and Research Institutes) 15.18. Rest of South America Opioid Tolerance Treatment Market Forecast, by Drug type 15.18.1. NMDA Antagonists 15.18.2. Alpha2-Adrenoceptor Agonists 15.18.3. Others 15.19. Rest of South America Opioid Tolerance Treatment Market Forecast, by Administration route 15.19.1. Enteral 15.19.2. Parenteral 15.19.3. Others (including Transdermal Route, Patches, and Cartons of Patches) 15.20. Rest of South America Opioid Tolerance Treatment Market Forecast, by End-use 15.20.1. Hospitals and ASCs 15.20.2. Rehabilitation Centers 15.20.3. Others (Homecare Settings and Research Institutes) 15.21. South America Opioid Tolerance Treatment Market Attractiveness Analysis 15.21.1. By Drug type 15.21.2. By Administration route 15.21.3. By End-use 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward Integration 16.3. Company Profiles: Key Players 16.3.1. Pfizer, 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. GlaxoSmithKline, 16.3.3. Boehringer Ingelheim, 16.3.4. Teva Pharmaceutical, 16.3.5. Mylan, 16.3.6. Otsuka Pharmaceutical, 16.3.7. Johnson & Johnson, 16.3.8. Aurobindo Pharma, 16.3.9. Acorda Therapeutics, 16.3.10. Zydus Cadila 16.3.11. Purdue Pharma, 16.3.12. Boehringer Ingelheim, 16.3.13. Janssen Pharmaceuticals, Inc., 16.3.14. Actavis Plc., Sanofi, 16.3.15. Sun Pharmaceutical Industries Ltd., 16.3.16. Mallinckrodt Pharmaceuticals 17. Primary Key Insights

About This Report

Report ID38807
Category Healthcare
Published DateNov 2019
No of Pages186
Contact Us